Treatment Response and Biomarker-Guided Steroid Taper for Children with GVHD

This phase II trial studies the treatment response for patients with acute graft-versus-host disease (GVHD). GVHD occurs when donor immune cells attack the healthy tissue of a bone marrow or stem cell transplant patient. The standard treatment for GVHD is to lower the activity of the donor cells by using steroid medications such as prednisone. But steroid treatment may cause many complications and the risk of these complications increases with higher doses of steroids and longer treatment. It is important to find ways to decrease the steroid treatment in patients who do not need long courses. Researchers are doing this study to find out how many subjects respond well to lower steroid dosing based on a blood test (GVHD biomarker) and if they develop fewer complications.

Disease Sites:

Miscellaneous, Pediatrics

Staging:

Phase II

Age Group:

Both

Therapies:

Therapy (NOS)

Drugs:

Prednisone

Principal Investigator(s):

Kitko, Carrie

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

08-30-2022

Trial Type:

Treatment

Protocol ID:

VICCPED2213

National Clinical Trial ID:

NCT05090384

Eligibility

Ages Eligible for Study:

0 Years

Genders Eligible for Study:

BOTH

Accepts Healthy Volunteers?:

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Treatment Response and Biomarker-Guided Steroid Taper for Children with GVHD

Eligibility